Literature DB >> 11738290

Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain.

Y Kawai1, E Tsukamoto, Y Nozaki, K Morita, M Sakurai, N Tamaki.   

Abstract

OBJECTIVES: To assess whether 15-(p-[iodine-123] iodophenyl)-3-(R,S) methylpentadecanoic acid (BMIPP) imaging can identify previous ischemic areas, BMIPP SPECT was performed in patients with acute chest pain to compare its findings with those of technetium-99m-tetrofosmin (tetrofosmin) SPECT and coronary angiography.
BACKGROUND: Basic studies indicate that BMIPP can identify previous ischemia as reduced tracer uptake.
METHODS: This study prospectively enrolled 111 consecutive patients with acute chest pain without myocardial infarction. Tetrofosmin SPECT was performed at rest within 24 h after the last episode of chest pain. Coronary angiography and BMIPP SPECT were also performed on the following day.
RESULTS: Sixty-four of the 87 patients with coronary stenosis or spasm showed BMIPP abnormalities corresponding to the areas of coronary abnormalities (sensitivity 74%), whereas only 33 of them showed perfusion abnormalities (sensitivity 38%) (p < 0.001). Of 24 patients [corrected] without coronary stenosis or spasm, 22 showed normal BMIPP SPECT (specificity = 92%) [corrected] and 23 showed normal tetrofosmin SPECT (sensitivity = 96%) [corrected]. Coronary stenosis was more often seen in the group with abnormal tetrofosmin/abnormal BMIPP (82%) and with normal tetrofosmin/abnormal BMIPP (69%) than in the group with normal tetrofosmin/normal BMIPP (36%) (p < 0.05). Coronary spasm was observed more often in the group with abnormal tetrofosmin/abnormal BMIPP (83%) and with normal tetrofosmin/abnormal BMIPP (90%) than in the group with normal tetrofosmin/normal BMIPP (27%) (p < 0.05). The extent and severity scores of tetrofosmin and BMIPP in the patients with organic stenosis were significantly higher than those of patients with no organic stenosis or spasm (p < 0.0001).
CONCLUSIONS: These data indicate that BMIPP SPECT may specifically identify previous ischemic lesions due to coronary stenosis or spasm in patients with acute chest pain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738290     DOI: 10.1016/s0735-1097(01)01634-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  42 in total

Review 1.  Imaging myocardial metabolic remodeling.

Authors:  Robert J Gropler; Rob S B Beanlands; Vasken Dilsizian; E Douglas Lewandowski; Flordeliza S Villanueva; Maria Cecilia Ziadi
Journal:  J Nucl Med       Date:  2010-05-01       Impact factor: 10.057

2.  Perfusion-BMIPP mismatch: specific finding or artifact?

Authors:  Koichi Morita; Eriko Tsukamoto; Nagara Tamaki
Journal:  Int J Cardiovasc Imaging       Date:  2002-08       Impact factor: 2.357

3.  Is BMIPP a sensitive marker for myocardial ischaemic stress? For.

Authors:  Nagara Tamaki; Koichi Morita
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-27       Impact factor: 9.236

4.  Is BMIPP a sensitive marker for myocardial ischaemic stress? Against.

Authors:  Robert J Gropler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-27       Impact factor: 9.236

Review 5.  Radionuclide imaging in risk assessment after acute coronary syndromes.

Authors:  J E Udelson; E J Flint
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

Review 6.  Targeted metabolic imaging to improve the management of heart disease.

Authors:  Moritz Osterholt; Shiraj Sen; Vasken Dilsizian; Heinrich Taegtmeyer
Journal:  JACC Cardiovasc Imaging       Date:  2012-02

Review 7.  Myocardial perfusion scintigraphy: past, present and future.

Authors:  A Notghi; C S Low
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

8.  Role of BMIPP imaging for risk stratification in patients with coronary artery disease.

Authors:  Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

Review 9.  Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations.

Authors:  Keiichiro Yoshinaga; Masanao Naya; Tohru Shiga; Eriko Suzuki; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-12       Impact factor: 9.236

Review 10.  Metabolic imaging using SPECT.

Authors:  Junichi Taki; Ichiro Matsunari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.